Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974004 | 0.88 | RXFP1 (0.47) | RXFP1POLBP2RX1KDRTP53 | |
| SCHEMBL4976902 | 0.87 | RXFP1 (0.49) | RXFP1SMN1; SMN2LMNAPOLBP2RX1 | |
| SCHEMBL4974926 | 0.85 | RXFP1 (0.45) | RXFP1SMN1; SMN2LMNAPOLBP2RX1 | |
| SCHEMBL4976222 | 0.85 | RXFP1 (0.47) | RXFP1SMN1; SMN2LMNAPOLBTSHR | |
| SCHEMBL4976395 | 0.81 | RXFP1 (0.46) | RXFP1LMNAPOLBKDRTP53 | |
| SCHEMBL3042696 | 0.81 | RXFP1 (0.47) | RXFP1LMNAPOLBUSP2TSHR | |
| SCHEMBL4465214 | 0.81 | RXFP1 (0.47) | RXFP1LMNAPOLBKDRMAPT | |
| SCHEMBL4973402 | 0.80 | TP53 (0.50) | RXFP1SMN1; SMN2LMNAPOLBHTT | |
| SCHEMBL4977894 | 0.78 | MAPT (0.56) | RXFP1SMN1; SMN2LMNAPOLBUSP2 | |
| SCHEMBL4975964 | 0.76 | RXFP1 (0.48) | RXFP1LMNAPOLBNR2E1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015222-A1 | New Heterocyclic Amides | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | claimed |
| EP-1797067-A1 | NEW HETEROCYCLIC AMIDES | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006033620-A1 | NEW HETEROCYCLIC AMIDES | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | claimed |
| US-20080015222-A1 | New Heterocyclic Amides | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| EP-1797067-A1 | NEW HETEROCYCLIC AMIDES | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006033620-A1 | NEW HETEROCYCLIC AMIDES | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015222-A1 | New Heterocyclic Amides | AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RXFP1 1473/4885SMN1; SMN2 4341/4885LMNA 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.